YPYounes Pilehvar-Soltanahmadi

Younes Pilehvar-Soltanahmadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Younes Pilehvar-Soltanahmadi has a total of 215 co-authors. Here are the top co-authors by number of shared publications:

  • Nosratollah Zarghami

    Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

    47 shared publications
  • Mehdi Dadashpour

    Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    17 shared publications
  • Effat Alizadeh

    The Umbilical Cord Stem Cell Research Center (UCSRC), Tabriz University of Medical Sciences, Tabriz, Iran

    7 shared publications
  • Nosratollah Zarghami

    Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran

    7 shared publications
  • Abolfazl Akbarzadeh

    6 shared publications
  • Faraz Zarghami

    Department of Clinical Biochemistry and Laboratory Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

    6 shared publications

Latest Publications

  • Open Access

    Hydrogel-mediated tri-modal nanoplatform for localized colorectal cancer therapy via smart chemo–photothermal–radiotherapy

    by Yanlong Shi, Sentai Ding, Zexin Wang, Leping Li, Jinshen Wang, Sepehr Mehdizadeh, Younes Pilehvar

    Colorectal cancer (CRC) remains difficult to eradicate locally because chemotherapy, photothermal therapy (PTT), and radiotherapy each have distinct limita


  • Open Access

    Advances in nanorobotics for gastrointestinal surgery: a new frontier in precision medicine and minimally invasive therapeutics

    by Zixuan Rui, Sepehr Mehdizadeh, Mozhgan Abasi, Younes Pilehvar

    Nanorobotics is catalyzing a paradigm shift in GI surgery by synergizing nanoscale engineering, synthetic biology, and intelligent computation to create a novel frontier in precision medicine. This review critically discusses the most recent experimental breakthroughs in surgical nanorobots—from bioinspired actuation to programmable materials to autonomous tumor ablation to closed-looped therapeutic feedback—and charts their development from static constructions to intelligent agents with the ability to navigate the dynamic gastrointestinal (GI) environment. Systematically, we review how nanorobots integrate with artificial intelligence (AI)-fortified platforms, overcome GI-specific obstacles, and can facilitate site-specific intervention with spatiotemporal precision. Based on state-of-the-art preclinical models, organoid studies in humans, and in vivo deployment, we analyze biodegradability, pharmacokinetics, and regulatory readiness in pursuit of first-in-human trials. Aside from technical innovation, this review also addresses grand challenges in autonomy, off-target control, and ethical-legal frameworks, calling for an integrated, cross-specialty format to facilitate clinical translation. In visualizing neural-controlled nanorobots, self-healing machines, and living biosensor networks, we outline the pathway towards intelligent, minimally invasive surgery at the molecular level. This work posits surgical nanorobotics not as an incremental innovation but as a transformative axis for convergent surgical therapeutics in the next generation. It is an academic wake-up call for the strategic coming of age in this field from experimental brilliance to translational inevitability.


  • Open Access

    Core-shell nanofiber dressings with zinc oxide nanoparticles and cell-free fat extract: boosting fibroblast activity and antibacterial efficacy

    by Aydin Mahmoudnezhad, Mahsa Bayrami, Mahdiyeh Saadati, Yavuz Nuri Ertaş, Mozhgan Abasi, Aylar Ebrahimi, Younes Pilehvar

    This study presents the development and characterization of innovative core-shell nanofiber wound dressings incorporating zinc oxide nanoparticles (nZnO) and cell-free fat extract (CEFFE) to enhance fibroblast activity and antibacterial efficacy. CEFFE was prepared and analyzed, revealing high concentrations of essential growth factors, particularly bFGF and TGF-β1, supporting its therapeutic potential in tissue regeneration. The fabricated nanofibers (PLCL, nZnO/PLCL, PLCL-CEFFE/HA, and nZnO/PLCL-CEFFE/HA) were examined using FE-SEM and TEM, demonstrating successful encapsulation and morphological variations due to nZnO incorporation. XRD analysis confirmed the structural integrity and effective loading of nZnO and CEFFE. Hydrophilicity assessment via water contact angle measurements showed that CEFFE/HA significantly enhanced the hydrophilicity of PLCL membranes, crucial for wound exudate management. Mechanical tests indicated that CEFFE/HA addition maintained the scaffold’s mechanical robustness, while nZnO slightly reduced mechanical properties. In vitro release studies revealed a biphasic release pattern of Zn²⁺ ions and growth factors from nZnO/PLCL-CEFFE/HA nanofibers, ensuring prolonged antibacterial activity and sustained therapeutic effects. Antibacterial assays demonstrated significant efficacy against E. coli and S. aureus, attributed to nZnO. MTT assays and FE-SEM analysis confirmed enhanced NIH-3T3 cell proliferation and adhesion on PLCL-CEFFE/HA nanofibers due to the controlled release of growth factors. The scratch assay showed superior cell migration and wound healing potential for PLCL-CEFFE/HA formulations. These findings underscore the potential of nZnO/PLCL-CEFFE/HA core-shell nanofibers as multifunctional wound dressings, combining antibacterial properties with enhanced tissue regeneration capabilities. However, further studies are needed to assess long-term stability and in vivo performance, which represent key challenges for future research.


  • Top Cited Papers
    Open Access

    Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies

    by Sepehr Mehdizadeh, Mobin Mamaghani, Somayyeh Hassanikia, Younes Pilehvar, Yavuz Nuri Ertas

    The blood-brain barrier (BBB) presents a formidable challenge in neuropharmacology, limiting the delivery of therapeutic agents to the brain. Exosomes, nature’s nanocarriers, have emerged as a promising solution due to their biocompatibility, low immunogenicity, and innate ability to traverse the BBB. A thorough examination of BBB anatomy and physiology reveals the complexities of neurological drug delivery and underscores the limitations of conventional methods. This review explores the potential of exosome-powered neuropharmaceutics, highlighting their structural and functional properties, biogenesis, and mechanisms of release. Their intrinsic advantages in drug delivery, including enhanced stability and efficient cellular uptake, are discussed in detail. Exosomes naturally overcome BBB barriers through specific translocation mechanisms, making them a compelling vehicle for targeted brain therapies. Advances in engineering strategies, such as genetic and biochemical modifications, drug loading techniques, and specificity enhancement, further bolster their therapeutic potential. Exosome-based approaches hold immense promise for treating a spectrum of neurological disorders, including Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), brain tumors, stroke, and psychiatric conditions. By leveraging their innate properties and engineering innovations, exosomes offer a versatile platform for precision neurotherapeutics. Despite their promise, challenges remain in clinical translation, including large-scale production, standardization, and regulatory considerations. Future research directions in exosome nanobiotechnology aim to refine these therapeutic strategies, unlocking new avenues for treating neurological diseases. This review underscores the transformative impact of exosome-based drug delivery, paving the way for next-generation therapies that can effectively penetrate the BBB and revolutionize neuropharmacology.


  • Precision Reimagined: CRISPR and Multiomics Transform Systemic Lupus Erythematosus Diagnosis and Therapy

    by Zhuo Chen, Elaheh Pilehvar, Hadi Sadeghi, Younes Pilehvar

    Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with diverse clinical manifestations and unpredictable progression, posing significant challenges to accurate diagnosis and effective treatment. Traditional biomarkers and treatments often fail to address the disease's molecular and clinical heterogeneity. Recent advancements in CRISPR gene‐editing technology and multiomics approaches offer transformative opportunities for personalized SLE care by unraveling its underlying molecular complexity and enabling precise therapeutic interventions. CRISPR technology allows targeted editing of SLE‐associated genetic mutations, addressing disease drivers directly, while multiomics—including genomics, transcriptomics, and proteomics—provides insights into dysregulated immune networks, identifying biomarkers and therapeutic targets. Integrating these approaches can refine patient stratification and enhance the precision of treatments. Artificial intelligence (AI) complements these technologies by synthesizing high‐dimensional data, enabling personalized treatment plans, predicting disease trajectories, and optimizing therapeutic strategies. However, the integration of CRISPR and multiomics in clinical settings raises challenges, including technical limitations, ethical concerns, and economic barriers. Emerging clinical trials and case studies demonstrate the potential of these innovations to personalize care and improve outcomes. Nonetheless, the transition from experimental research to routine clinical application requires robust regulatory frameworks and strategies to address these challenges. This review aims to explore the potential of CRISPR and multiomics technologies to revolutionize SLE diagnosis and therapy, emphasizing their integration with AI to advance personalized care. By addressing existing barriers, the review envisions a future where precision medicine transforms SLE management, paving the way for individualized, patient‐centered autoimmune therapy.


  • Implantable smart hyperthermia nanofibers for cancer therapy: Challenges and opportunities

    by Amir Valizadeh, Samira Asghari, Saleheh Abbaspoor, Abbas Jafari, Mortaza Raeisi, Younes Pilehvar

    Nanofibers (NFs) with practical drug‐loading capacities, high stability, and controllable release have caught the attention of investigators due to their potential applications in on‐demand drug delivery devices. Developing novel and efficient multidisciplinary management of locoregional cancer treatment through the design of smart NF‐based systems integrated with combined chemotherapy and hyperthermia could provide stronger therapeutic advantages. On the other hand, implanting directly at the tumor area is a remarkable benefit of hyperthermia NF‐based drug delivery approaches. Hence, implantable smart hyperthermia NFs might be very hopeful for tumor treatment in the future and provide new avenues for developing highly efficient localized drug delivery systems. Indeed, features of the smart NFs lead to the construction of a reversibly flexible nanostructure that enables hyperthermia and facile switchable release of antitumor agents to eradicate cancer cells. Accordingly, this study covers recent updates on applications of implantable smart hyperthermia NFs regarding their current scope and future outlook.This article is categorized under: Implantable Materials and Surgical Technologies > Nanomaterials and Implants


  • Epidural Administration of Curcumin-Loaded Polycaprolactone/Gelatin Electrospun Nanofibers for Extended Analgesia After Laminectomy in Rats

    by Tingting Jiang, Yu Han, Niloufar Esmaeilizadeh, Amin Barkhordari, Abduladheem Turki Jalil, Marwan Mahmood Saleh, Sona Talaei, Younes Pilehvar

    Several clinical studies have reported the analgesic effect of curcumin (Curc) in various situations such as rheumatoid arthritis, osteoarthritis, and postsurgical pain. Therefore, in this work, Curc-loaded electrospun nanofibers (NFs) are designed to evaluate their sustained release on analgesic effect duration in rats after epidural placement via repeated formalin and tail-flick tests. The Curc-loaded polycaprolactone/gelatin NFs (Curc-PCL/GEL NFs) are prepared through an electrospinning technique and introduced to the rat’s epidural space after laminectomy. The physicochemical and morphology features of the prepared Curc-PCL/GEL NFs were characterized via FE-SEM, FTIR, and degradation assay. The in vitro and in vivo concentrations of Curc were measured to evaluate the analgesic efficacy of the drug-loaded NFs. Rat nociceptive responses are investigated through repeated formalin and tail-flick tests for 5 weeks after the placement of NFs. Curc had a sustained release from the NFs for 5 weeks, and its local pharmaceutical concentrations were much greater than plasma concentrations. Rat’s pain scores in both early and late phases of the formalin test were remarkably decreased in the experimental period. Rat’s tail-flick latency was remarkably enhanced and remained constant for up to 4 weeks. Our findings show that the Curc-PCL/GEL NFs can supply controlled release of Curc to induce extended analgesia after laminectomy.


  • Curcumin-Loaded Mesenchymal Stem Cell–Derived Exosomes Efficiently Attenuate Proliferation and Inflammatory Response in Rheumatoid Arthritis Fibroblast-Like Synoviocytes

    by Xinghong He, Chong Zhang, Soumaye Amirsaadat, Abduladheem Turki Jalil, Mustafa M. Kadhim, Mozhgan Abasi, Younes Pilehvar

    This study aimed to evaluate the potential of mesenchymal stem cell–derived exosomes loaded with curcumin (Curc-Exos) as an effective therapeutic strategy for rheumatoid arthritis through modulation of proliferation and inflammatory response in HIG-82 synovial cells. For this purpose, Exos were isolated and characterized with BCA protein assay, DLS, FE-SEM, and TEM. The Curc was embedded by mixing it with Exos in a 1:4 ratio. It was found that the Curc stability has improved after loading on Exos compared to the free Curc. Besides, the in vitro studies using LPS-stimulated HIG-82 synovial cells indicated the efficiency of Curc-Exos in enhancing cytotoxicity and apoptosis compared to the free Curc treatment. It was also revealed that Curc-Exos significantly could reduce the expression levels of anti-apoptotic proteins IAP1 and IAP2 and inflammatory mediators including IL-6, TNF-α, MMP1, and PGE2. This preliminary study confirmed the suitability of Curc-Exos in counteracting the proliferation and inflammatory response of rheumatoid arthritis synovial fibroblasts in vitro.